Prolia, New Treatment for Osteoporosis, Approved by FDA
Therapy to strengthen bones with injections called Prolia has been approved by the US Food and Drug Administration (FDA). This drug is intended to reduce damage and increase bone mass and bone strength in postmenopausal women.
Osteoporosis is a condition of reduced bone density so that the bones become fragile and easily broken. Approximately 80 percent of osteoporosis cases occur in women, although men can also experience it. According to the FDA, half of women age above 50 years have experienced bone fractures due to osteoporosis.
With this Prolia, fracture risk and its complications can be prevented. Prolia injection is made by Amgen and recommended to be injected once a month.
“Because the large prevalence, osteoporosis is a serious health problem. The approval of Prolia can give hope to women suffering from osteoporosis menopasue and susceptible to fracture,” said Dr.Julie Beitz, director of FDA’s drug evaluation.
Safety and efficacy of Prolia on menopausal osteoporosis in women has been demonstrated in a three-year study of 7808 women aged 60-91 years. In that study, it is proved that Prolia is capable to reduce the incidence of bone fractures in the hip, vertebral and non-vertebral.
Every drug surely has side effects. Prolia is reported to cause side effects such as back pain, muscle aches, increased cholesterol, and urinary tract infections. More serious side effects such as hypocalcaemia (low calcium levels in the blood), skin infections and skin reactions such as dermatitis and itching.